1-6 of 6
Jeffrey Crawford
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

Jeffrey Crawford, Roberto A. Calle, Susie M. Collins, Yan Weng, Shannon L. Lubaczewski, Clare Buckeridge, Ellen Q. Wang, Magdalena A. Harrington, Anil Tarachandani, Michelle I. Rossulek, James H. Revkin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 489–497.
https://doi.org/10.1158/1078-0432.CCR-23-1631
Published: 01 February 2024
View article titled, A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Open the PDF for A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia in another window
Includes: Supplementary data
Journal Articles

Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

John S. Yi, Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, Jeffrey Clarke, Jeffrey Crawford, Betty Tong, David Harpole, Thomas A. D'Amico, Frances McSherry, Frank Dunphy, Shannon J. McCall, Jared D. Christensen, Xiaofei Wang, Kent J. Weinhold
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7474–7482.
https://doi.org/10.1158/1078-0432.CCR-17-2005
Published: 14 December 2017
View article titled, Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
Open the PDF for Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab in another window
Includes: Supplementary data
Journal Articles

Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma

Marvaretta Stevenson, William Mostertz, Chaitanya Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, Sascha A. Tuchman, Jeffrey Crawford, Gordana Vlahovic, Neal Ready, Mark Onaitis, Anil Potti
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7553–7561.
https://doi.org/10.1158/1078-0432.CCR-09-1939
Published: 14 December 2009
View article titled, Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma
Open the PDF for Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

Louis M. Weiner, Arie S. Belldegrun, Jeffrey Crawford, Anthony W. Tolcher, Pamela Lockbaum, Rosalin H. Arends, Lynn Navale, Rafael G. Amado, Gisela Schwab, Robert A. Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 502–508.
https://doi.org/10.1158/1078-0432.CCR-07-1509
Published: 25 January 2008
View article titled, Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
Open the PDF for Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies in another window
Journal Articles

Concurrent Chemoradiotherapy for Unresectable Stage III Non–Small Cell Lung Cancer

Everett E. Vokes, Jeffrey Crawford, Jeffrey Bogart, Mark A. Socinski, Gerald Clamon, Mark R. Green
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 5045s–5050s.
https://doi.org/10.1158/1078-0432.CCR-05-9008
Published: 06 July 2005
View article titled, Concurrent Chemoradiotherapy for Unresectable Stage III Non–Small Cell Lung Cancer
Open the PDF for Concurrent Chemoradiotherapy for Unresectable Stage III Non–Small Cell Lung Cancer in another window
Journal Articles

Postremission Therapy with Low-dose Interleukin 2 with or without Intermediate Pulse Dose Interleukin 2 Therapy Is Well Tolerated in Elderly Patients with Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 9420

Sherif S. Farag, Stephen L. George, Edward J. Lee, Maria Baer, Richard K. Dodge, Brian Becknell, Todd Fehniger, Lewis R. Silverman, Jeffrey Crawford, Clara D. Bloomfield, Richard A. Larson, Charles A. Schiffer, Michael A. Caligiuri
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 2812–2819.
Published: 01 September 2002
View article titled, Postremission Therapy with Low-dose Interleukin 2 with or without Intermediate Pulse Dose Interleukin 2 Therapy Is Well Tolerated in Elderly Patients with Acute Myeloid Leukemia: <subtitle>Cancer and Leukemia Group B Study 9420</subtitle>
Open the PDF for Postremission Therapy with Low-dose Interleukin 2 with or without Intermediate Pulse Dose Interleukin 2 Therapy Is Well Tolerated in Elderly Patients with Acute Myeloid Leukemia: <subtitle>Cancer and Leukemia Group B Study 9420</subtitle> in another window